Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026
Basics
Sector
Healthcare
Industry
Healthcare Plans
Country
United States
Market cap
50.2B USD
Enterprise value
40.0B USD
Full-time employees
67,060
Overall health
Strength:its shares are priced lower than most peers relative to what it earnspriced lower than peers for its earnings
Drawback:higher risk than most peers: more debt relative to equity (0.74× vs a peer median of 0.22×)higher risk: more debt vs equity (0.74× vs peers 0.22×)
About average: profitability and growth
Ranks #646 of 1,157 healthcare companies (bottom 45%)
Why it changed since the Oct 27, 2026 close: Score 49 → 50
Peer companies moved+1
Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.
Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.
Questions investors ask about Humana
Is Humana getting weaker?
Its latest SEC filing (Jul 29, 2026) showed no major changes. Its overall score is unchanged at 49/100 since Oct 28, 2026.
How is Humana valued vs its peers?
Priced lower than most peers relative to what it earns. Valuation scores 64/100 against 1,393 healthcare peers.EBITDA yield 8.3% vs a peer median of 4.0% (stronger than 75% of peers).EBITDA yield 8.3% vs peers 4.0% (stronger than 75% of peers).
Is Humana growing?
At about the same pace as its peers. Growth scores 58/100 against 1,393 healthcare peers.Revenue growth 18.3% vs a peer median of 6.1% (stronger than 76% of peers).Revenue growth 18.3% vs peers 6.1% (stronger than 76% of peers).Earnings per share growth -18.7% vs a peer median of 9.8% (weaker than 69% of peers).Earnings per share growth -18.7% vs peers 9.8% (weaker than 69% of peers).
How profitable is Humana?
About as profitable as its peers. Profitability scores 50/100 against 1,393 healthcare peers.Return on invested capital 8.0% vs a peer median of 4.7% (stronger than 61% of peers).Return on invested capital 8.0% vs peers 4.7% (stronger than 61% of peers).Operating margin 1.9% vs a peer median of 7.1% (weaker than 64% of peers).Operating margin 1.9% vs peers 7.1% (weaker than 64% of peers).
How risky is Humana?
Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings.Debt / equity 0.74× vs a peer median of 0.22× (weaker than 76% of peers).Debt / equity 0.74× vs peers 0.22× (weaker than 76% of peers). A relative measure, not a bankruptcy probability.
Latest filing: what changed
Quarter ended Jun 30, 2026 · filed Jul 29, 2026 · compared with the quarter ended Mar 31, 2026
No major changes
Previous quarter
Latest quarter
Change
Revenue (12 months)
137.2B USD
145.7B USD
+6.2%
Net income (12 months)
1.1B USD
1.3B USD
+13.2%
Operating margin
1.8%
1.9%
+0.1 pts
Free cash flow (12 months)
1.3B USD
1.9B USD
+53.2%
Debt
14.0B USD
14.2B USD
+1.8%
Cash
5.0B USD
6.9B USD
+39.2%
From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.
Industry valuation context
Sector: Healthcare · 301 companies
Valuations in Healthcare are within their usual range since 2016.
52% of months since 2016 were valued lower than now.
19% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values +8% and earnings +24% (medians): earnings grew faster than prices.
Median price-to-sales is +63% vs the whole market, against a usual +119%.
2016Shaded: most expensive fifth of its range2026
Shown for Healthcare: too few Healthcare Plans companies have a long enough history of their own.
Earnings-based measures are left out for now because many companies in Healthcare are losing money.
Describes valuations since 2016; it does not predict prices. US companies worth $1B+, from SEC filings and month-end prices, as of Aug 2026. Today's companies and industry labels are used throughout. Measured on sales and free cash flow yields. How this works
Financials
Fiscal years from SEC annual filings · change vs the prior year
Key ratios
FY 2021
FY 2022
FY 2023
FY 2024
FY 2025
Change
Operating margin
3.8%
4.1%
3.8%
2.2%
2.1%
▼ 0.1 pts
Net margin
3.5%
3.0%
2.3%
1.0%
0.9%
▼ 0.1 pts
Return on assets (ROA)
6.6%
6.5%
5.3%
2.6%
2.4%
▼ 0.2 pts
Return on equity (ROE)
18.2%
18.3%
15.3%
7.4%
6.7%
▼ 0.6 pts
Debt to equity
0.78×
0.73×
0.72×
0.72×
0.70×
▼ 2.1%
Interest coverage
9.66×
9.48×
8.14×
3.88×
4.29×
▲ 10%
HUM price history
Price history is added with the daily price update and will appear after the next one.